Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

P4HA1 knockdown in the breast cell line MDA231 (part III)

ABSTRACT: Determine the effect of knocking down P4HA1 in the MDA231 cell line (including alterations to metabolic pathways).Control versus knockdown

ORGANISM(S): Human Homo Sapiens

TISSUE(S): Cultured Cells

DISEASE(S): Cancer

SUBMITTER: Gaofeng Xiong

PROVIDER: ST001129 | MetabolomicsWorkbench | Wed Jan 30 00:00:00 GMT 2019

REPOSITORIES: MetabolomicsWorkbench

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	mwtab	Other

Items per page:

1 - 1 of 1

Similar Datasets

P4HA1 knockdown in the breast cell line MDA231 (part I)

Project description:Determine the effect of knocking down P4HA1 in the MDA231 cell line (including alterations to metabolic pathways). Control versus knockdown

2018-09-12 | ST001049 | MetabolomicsWorkbench

P4HA1 knockdown in the breast cell line MDA231 Gln metabolism (part VI)

Project description:Determine the effect on glutamine metabolism of knocking down P4HA1 in the MDA231 cell line.

2019-02-15 | ST001139 | MetabolomicsWorkbench

P4HA1 knockdown in the breast cell line MDA231 Gln metabolism (part V)

Project description:Determine the effect on glutamine metabolism of knocking down P4HA1 in the MDA231 cell line.

2019-02-15 | ST001138 | MetabolomicsWorkbench

P4HA1 knockdown in the breast cell line MDA231 Gln metabolism (part II)

Project description:Determine the effect on glutamine metabolism of knocking down P4HA1 in the MDA231 cell line.

2018-09-12 | ST001050 | MetabolomicsWorkbench

Gene expression profiling of MDA231 cells with alterations involving beta-oxidation pathway

Project description:In order to confirm the role of fatty acid Î²-oxidation in Src regulation, we performed gene expression analysis in MDA231 cells from in vivo model treated with ETX or knockdown of CPT1 or CPT2 using shRNA. As expected, inhibition of Î²-oxidation showed a gene expression pattern that is opposite to the published Src regulated gene pattern. The known Src up-regulated genes are down-regulated and Src down-regulated genes are up-regulated in Î²-oxidation inhibited cells. Western Blotting further confirmed the gene expression pattern. Knockdown of CPT1 or CPT2 inhibited Src Y416 autophosphorylation as observed with ETX. MDA231 cells were treated with ETX or knockdown of CPT1 or CPT2 using shRNA. Gene expression profiles were taken for each group and compared with control group (shRNA scramble). Multiple group comparison [MDA231-Scramble (C), MDA231-Scramble +ETX (D), MDA231-shCPT-1 (E) and MDA231-shCPT-2 (F)]

2016-04-14 | E-GEOD-72320 | biostudies-arrayexpress

Immunotherapy for breast cancer using EpCAM aptamer tumor-targeted gene knockdown efficacy_UPF2 knockdown in EpCAMhi MDA-MB-231 breast cancer cell lines

Project description:Knocking down Upf2, which encodes a protein that binds to prematurely terminated mRNAs to activate NMD, has been postulated to induce tumor cell expression of neoantigens to promote tumor recognition by T cells. To investigate whether Upf2 knockdown in breast cancer generates novel mRNA isoforms, we performed bulk RNA sequencing (RNA-seq) to compare an EpCAMhi MDA-MB-231 human breast cancer cell line transfected with noncoding control or UPF2 siRNA for 72 h. Results: 222 examples of differential exon usage (DEU) within 281 genes were identified. The number and diversity of DEUs suggest that UPF2 knockdown could have caused novel alternative splicing. To test this idea, UPF2 knockdown-related transcriptional diversity was deconvoluted to identify and estimate the abundance of transcript isoforms. 42 genes with potential differential isoform usage (DIU) were identified. Collectively, our data suggest that reducing NMD activity by UPF2 knockdown may induce expression of tumor neoantigens.

2021-02-05 | GSE156185 | GEO

Genome wide mapping of effects of U6atac knockdown on pre-mRNA splicing

Project description:This project looks into experimentally identifying all minor introns by knocking down the minor spliceosome's catalytic snRNP, U6atac. Knockdown of U6atac by antisense morpholino followed by examining mRNA splicing by RNA-seq

2013-08-01 | E-GEOD-48263 | biostudies-arrayexpress

Immunotherapy for breast cancer using EpCAM aptamer tumor-targeted gene knockdown efficacy

Project description:New strategies for cancer immunotherapy are needed since most solid tumors do not respond to current approaches. Here, we used EpCAM aptamer-linked small interfering RNAs (aptamer-siRNA chimeras (AsiCs)) to knockdown genes selectively in EpCAM+ tumors with the goal of making cancers more visible to the immune system to improve anti-tumor immunity. Gene targets were chosen whose knockdown was predicted to promote tumor neoantigen expression (Upf2 and Parp1), phagocytosis and antigen presentation (Cd47), or cause tumor cell death (Mcl1). Using scRNA-seq, we showed that knocking down the four targets simutaeoulsy potently improved the anti-tumor immunity mediated T cells and macrophage/monocytes, demonstrating the immunostimulatory capacity of EpCAM-AsiCs.

2021-02-05 | GSE156214 | GEO

RNA Sequencing of Ishikawa Cell Line with NCF2 Knockdown Using Small Interfering RNA

Project description:Progestin therapy is one of the preferred treatment modalities for early-stage endometrial cancer patients wishing to retain fertility and for conservatively managing advanced endometrial cancer. However, a significant number of patients currently do not benefit from progestin therapy due to issues such as progestin resistance. In the past, we established a medroxyprogesterone acetate-resistant Ishikawa cell line. From this, we identified the NCF2 gene, which was highly expressed in the resistant group. Functional validation experiments revealed that knocking down NCF2 can effectively reverse progestin resistance. To explore its mechanism, we performed RNA sequencing post-NCF2 knockdown.

2024-06-30 | GSE242226 | GEO

Expression data from ovarian cancer with CHSY1 knockdown

Project description:CHSY1 has high expression in malignant tumor cells, such as colorectal cancer and ovarian cancer, and is associated with poor prognosis.The proliferation and invasion of ovarian cancer cells are weakened after knocking down CHSY1 with shRNA transfected We used microarrays to detail the global programme of gene expression underlying CHSY1 knockdown and identified distinct classes of up-regulated and down-regulated genes.

2024-05-01 | GSE232722 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data